There has been recent interest into the question whether PSMA scanning can be avoided for GGG 1-3 men before starting SRT for BCR after RP. For example:
IDENTIFICATION OF THE BEST CANDIDATES FOR PSMA PET/CT AMONG PATIENTS EXPERIENCING BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY (2021)
"Abstract
INTRODUCTION AND OBJECTIVE:
Although PSMA PET/CT is recommended in the biochemical recurrence (BCR) setting after radical prostatectomy (RP), its impact on clinical management is unclear. This is particularly true when considering prostate cancer (PCa) patients at low risk of metastases who could be managed with salvage radiotherapy (sRT) alone. We aimed at assessing when PSMA PET/CT could be safely avoided or postponed
METHODS:
182 patients evaluated with PSMA PET/CT for BCR after RP between 2016 and 2020 were evaluated. The outcome was a distant metastasis (i.e., retroperitoneal, skeletal or visceral) at PSMA PET/CT. Multivariable logistic regression analyses assessed predictors of distant spots (i.e., pathological stage, grade group, sRT and ADT). The model based on the regression coefficients was internally validated. An interaction analysis tested whether the association between PSA at PET/CT and distant spots varied according to the risk calculated using the model. Patients were stratified according to the model-derived risk (<30 vs. ≥30%) and the rate of distant spots at PET/CT was plotted against PSA values
RESULTS:
Median PSA at PET/CT scan was 0.7 ng/ml. Overall, 76 (41.5%) and 57 (31.1%) had grade group 4-5 and seminal vesicle invasion (SVI). Overall, 60 (32.8%) and 24 (13.1%) patients received sRT and ADT before PSMA PET/CT. Overall, 59 (32.2%) patients had distant spots at PSMA PET/CT. Concomitant ADT (Hazard Ratio [HR]: 5.5; p=0.02), SVI (HR:3.5; p=0.005) and grade group 4-5 (HR:3.7; p=0.01) predicted distant spots at PET/CT (AUC: 80%). The rate of distant positive spots in men with grade group 1-3, no SVI and no ADT (n=34, 18.6%) was 12%. This increased to 41% in patients with adverse factors (p<0.001). The impact of PSA values at PSMA PET/CT varied according to the novel risk score (p=0.03 by interaction test). While in men with a calculated risk <30% increasing PSA values at PSMA PET/CT did not impact on the risk of distant metastases at PSMA PET/CT, in those with worse characteristics it increased according to PSA levels.
CONCLUSIONS:
The use of PSMA PET/CT can be safely avoided or postponed in individuals with grade group 1-3, no SVI and who did not receive previous salvage therapies. These patients can be considered candidates to sRT without a previous PSMA PET/CT."(See graph)
I would think a Decipher test on the RP tissue would be helpful in the decision-making.
Djin